SigTuple, a MedTech startup based in Bengaluru, has raised $4 million (over INR 33.5 crore) in an extended Series C round of funding. The latest funding was spearheaded by Sidbi Venture Capital and other usual backers such as Endiya Partners. SigTuple aims to use the newly acquired capital to break into new markets and healthcare systems.
Image Source: SigTuple
Vision of SigTuple
SigTuple aims to advance the product portfolio significantly. The company specializes in providing solutions in diagnostics and managing health care with products and services. With the new funding, SigTuple aims to expand talent and work on advanced technologies that would enhance patient outcomes.
Working on Sigtuple’s Technology
SigTuple’s technology uses Artificial intelligence (AI) and Machine Learning (ML) to assist with medical diagnostics. Diagnostic images include blood smears, urine tests, or retinal scans, and are taken using image-capturing equipment. The acquired images are then preprocessed to improve the image quality, eliminate random noise on images, and make them comparable for analysis.
SigTuple performs feature extraction from the images. These features could be morphology, color, texture, or any other features in the cell. In SigTuple, the initial features are passed through ML models like convolutional neural networks. Such models are trained on labeled data to learn patterns and correlations between features.
Using the learned patterns, the system of SigTuple classifies the images. It can detect various blood components in blood smears, including red blood cells, white blood cells, and platelets. In retinal scans, it can look for signs of diabetic retinopathy or other problems with the eyes. The system generates relevant information for healthcare professionals, helping in diagnosis and treatment decisions.
Impressive Track Record
The fund infusion will go toward regulatory clearances for SigTuple’s sophisticated offerings, which will total $4 million. Nevertheless, the company is set to grow and, with its help, improve healthcare through the implementation of new technologies. This round of funding augments SigTuple’s portfolio quite significantly. The company in the previous Series C round managed to attract $19 million and it seems that investors believe in its idea and management team. The mission set by SigTuple of building a healthier future through technology makes the company a strong contender in the medtech sector.
Usage of SigTuple Technology on other applications
SigTuple specializes in pathology and ophthalmology, providing solutions enhanced by artificial intelligence (AI). SigTuple’s AI100 is a fully intelligent and autonomous digital microscope. It scans microscopes such as the blood smear or tissue slide to produce sharp, digital images. This technology supplanted time-consuming microscope analysis, thus improving diagnosis efficiency, accuracy, and affordability. These images can be viewed remotely by pathologists which can enhance productivity while collaborating.
The digital scans produced by the AI100 microscope are processed by SigTuple’s AI platform. The software categorizes cells into more than thirty types which enable accurate diagnosis to be made. Examples are blood cell counting, urine examination, and many others. The technology used by SigTuple helps in telepathology by allowing pathologists from different regions to work together. It improves the availability of professional advice and accelerates time-consuming essential diagnoses. Using robotics, AI, and cloud computing, SigTuple is set to democratize diagnosis. They deliver solutions that enable quality medical care to be available, precise, and cheap.
Conclusion
SigTuple’s latest funding round indicates its growth path and proves it is focused on delivering innovations. The company’s strategic emphasis on diversification of its products and pursuing relevant approval is indicative of its commitment to advancing the well-being of patients. SigTuple’s technology fundamentally changes the nature of pathology and ophthalmology for patients and doctors.
Disclaimer – We have collected this information from various trustworthy sources on the Internet, and the facts have been checked manually and verified by our In House team.
